MgO, Mg2SiO4, and MgO/Mg2SiO4 nanostructures were synthesized, and their luminescence properties were investigated. The morphological and structural properties of the MgO nanostructures were also characterized. Sponge-like MgO particles with layered nanosheet structures were synthesized by thermally annealing MgCl2 in air. The MgO nanostructures exhibited a cathodoluminescence emission peak at 5.2 eV with a small peak at 2.4 eV. The Mg2SiO4 and MgO/Mg2SiO4 nanostructures were also synthesized by annealing MgCl2 with CaSi2. Mg2SiO4 domains were formed on the surface of the MgO particles. Two main emission peaks were observed for the MgO/Mg2SiO4 nanostructures—one at approximately 5.2 eV and another in the range of 2.4–3.4 eV. Compared to MgO, the photoluminescence characteristics of the MgO/Mg2SiO4 nanostructures were modified, and the emission peaks were shifted. The formation of Mg2SiO4 with MgO expanded the visible–ultraviolet emission regions from 2.4 to 3.4 eV under cathode-ray excitation, followed by a shift from 2.1 to 2.0 eV under photo excitation.
Conventional systemic drug delivery often yields low efficacy and significant side effects due to off-target accumulation and rapid clearance. While nanoscale carriers leverage the enhanced permeability and retention (EPR) effect, this passive targeting is unreliable because tumor vascular heterogeneity leads to widely variable nanoparticle accumulation. As an alternative, untethered micro- and nanorobots (MNRs) have been engineered to actively navigate through complex fluids and autonomously deliver payloads to previously inaccessible sites. These autonomous biohybrids integrate nanoscale actuators, sensors, and computational units to enable precise, on-demand therapeutic actions at the cellular level. In particular, integrating artificial intelligence endows nanorobots with advanced sensing and decision-making capabilities: they can analyze molecular biomarkers and map biological pathways in real time to determine optimal treatment plans, yielding highly personalized, responsive therapies with enhanced efficacy. We also examine strategies for post-treatment removal of MNRs, emphasizing immune-compatible, biodegradable designs that allow metabolic clearance. This review aims to provide a comprehensive, in-depth, and nuanced examination of nanorobots in medical applications mainly in cancer treatments. Finally, we highlight remaining technical, manufacturing, regulatory and ethical challenges such as ensuring biocompatibility, scalable fabrication, and rigorous safety evaluation that must be ad-dressed for clinical translation.